Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial
Identifieur interne : 000179 ( Istex/Curation ); précédent : 000178; suivant : 000180Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial
Auteurs : Christopher G. Goetz [États-Unis] ; Philippe Damier [France] ; Christine Hicking [Allemagne] ; Eugene Laska [États-Unis] ; Thomas Müller [Allemagne] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-01-15.
English descriptors
Abstract
The objective of this study is to conduct a dose‐finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5‐HT1A agonist properties and additional high affinity for D3 and D4 receptors. An open label study documented improvements in PD patients with levodopa‐induced dyskinesia. There is no precedent for study designs or outcome measures in pivotal trials of antidyskinesia therapies. The approach used here was a multicenter, randomized, placebo‐controlled, double‐blind, parallel study. Included were PD patients optimized to levodopa and dopaminergic drugs with moderately disabling dyskinesias present greater than or equal to 25% of the waking day. Interventions included sarizotan 2, 4, or 10 mg/day or matching placebo, given in two doses. There were two outcome measures: the primary measure was change from baseline in diary‐based on time without dyskinesia; the secondary measures were change from baseline in scores on the Abnormal Involuntary Movement Scale (AIMS), the composite score of Unified Parkinson's Disease Rating Scale (UPDRS) Items 32+33 (dyskinesia duration and disability) and total UPDRS. A total of 398 subjects were randomized, with 381 included in the intention‐to‐treat population. No significant changes occurred on sarizotan compared to placebo on any diary‐based measure of dyskinesia or the AIMS score. The composite score of UPDRS Items 32+33 was significantly improved with 2 mg/day sarizotan, with a trend at 10 mg/day. Adverse events were not significantly different in sarizotan‐ and placebo‐treated patients, but off time significantly increased with sarizotan 10 mg/day. Sarizotan 2 mg/day is a safe agent in PD patients with dyskinesia. To test its role in abating dyskinesia, future studies should focus on this dose and will use the composite score of UPDRS Items 32+33 as the primary outcome. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21226
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000179
Links to Exploration step
ISTEX:0DE4A22F865B7A74E84AF35376BF9D26DF62324CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="1"><mods:affiliation>Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Rush University Medical Center, Chicago, Illinois</wicri:regionArea></affiliation></author><author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name><affiliation wicri:level="1"><mods:affiliation>Hôpital Guillaume et René Laennec, Nantes, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Guillaume et René Laennec, Nantes</wicri:regionArea></affiliation></author><author><name sortKey="Hicking, Christine" sort="Hicking, Christine" uniqKey="Hicking C" first="Christine" last="Hicking">Christine Hicking</name><affiliation wicri:level="1"><mods:affiliation>Merck KGaA, Darmstadt, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Merck KGaA, Darmstadt</wicri:regionArea></affiliation></author><author><name sortKey="Laska, Eugene" sort="Laska, Eugene" uniqKey="Laska E" first="Eugene" last="Laska">Eugene Laska</name><affiliation wicri:level="1"><mods:affiliation>New York University School of Medicine, New York, and Nathan Kline Institute, Orangeburg, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>New York University School of Medicine, New York, and Nathan Kline Institute, Orangeburg, New York</wicri:regionArea></affiliation></author><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name><affiliation wicri:level="1"><mods:affiliation>Ruhr University, Bochum, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Ruhr University, Bochum</wicri:regionArea></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation wicri:level="1"><mods:affiliation>Mount Sinai School of Medicine New York, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mount Sinai School of Medicine New York, New York</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Toulouse University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Russ, Hermann" sort="Russ, Hermann" uniqKey="Russ H" first="Hermann" last="Russ">Hermann Russ</name><affiliation wicri:level="1"><mods:affiliation>Merck KGaA, Darmstadt, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Merck KGaA, Darmstadt</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0DE4A22F865B7A74E84AF35376BF9D26DF62324C</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21226</idno><idno type="url">https://api.istex.fr/document/0DE4A22F865B7A74E84AF35376BF9D26DF62324C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000179</idno><idno type="wicri:Area/Istex/Curation">000179</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="1"><mods:affiliation>Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Rush University Medical Center, Chicago, Illinois</wicri:regionArea></affiliation></author><author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name><affiliation wicri:level="1"><mods:affiliation>Hôpital Guillaume et René Laennec, Nantes, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Guillaume et René Laennec, Nantes</wicri:regionArea></affiliation></author><author><name sortKey="Hicking, Christine" sort="Hicking, Christine" uniqKey="Hicking C" first="Christine" last="Hicking">Christine Hicking</name><affiliation wicri:level="1"><mods:affiliation>Merck KGaA, Darmstadt, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Merck KGaA, Darmstadt</wicri:regionArea></affiliation></author><author><name sortKey="Laska, Eugene" sort="Laska, Eugene" uniqKey="Laska E" first="Eugene" last="Laska">Eugene Laska</name><affiliation wicri:level="1"><mods:affiliation>New York University School of Medicine, New York, and Nathan Kline Institute, Orangeburg, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>New York University School of Medicine, New York, and Nathan Kline Institute, Orangeburg, New York</wicri:regionArea></affiliation></author><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name><affiliation wicri:level="1"><mods:affiliation>Ruhr University, Bochum, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Ruhr University, Bochum</wicri:regionArea></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation wicri:level="1"><mods:affiliation>Mount Sinai School of Medicine New York, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mount Sinai School of Medicine New York, New York</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Toulouse University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Russ, Hermann" sort="Russ, Hermann" uniqKey="Russ H" first="Hermann" last="Russ">Hermann Russ</name><affiliation wicri:level="1"><mods:affiliation>Merck KGaA, Darmstadt, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Merck KGaA, Darmstadt</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01-15">2007-01-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="179">179</biblScope><biblScope unit="page" to="186">186</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0DE4A22F865B7A74E84AF35376BF9D26DF62324C</idno><idno type="DOI">10.1002/mds.21226</idno><idno type="ArticleID">MDS21226</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dyskinesias</term><term>randomized clinical trials</term><term>sarizotan</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study is to conduct a dose‐finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5‐HT1A agonist properties and additional high affinity for D3 and D4 receptors. An open label study documented improvements in PD patients with levodopa‐induced dyskinesia. There is no precedent for study designs or outcome measures in pivotal trials of antidyskinesia therapies. The approach used here was a multicenter, randomized, placebo‐controlled, double‐blind, parallel study. Included were PD patients optimized to levodopa and dopaminergic drugs with moderately disabling dyskinesias present greater than or equal to 25% of the waking day. Interventions included sarizotan 2, 4, or 10 mg/day or matching placebo, given in two doses. There were two outcome measures: the primary measure was change from baseline in diary‐based on time without dyskinesia; the secondary measures were change from baseline in scores on the Abnormal Involuntary Movement Scale (AIMS), the composite score of Unified Parkinson's Disease Rating Scale (UPDRS) Items 32+33 (dyskinesia duration and disability) and total UPDRS. A total of 398 subjects were randomized, with 381 included in the intention‐to‐treat population. No significant changes occurred on sarizotan compared to placebo on any diary‐based measure of dyskinesia or the AIMS score. The composite score of UPDRS Items 32+33 was significantly improved with 2 mg/day sarizotan, with a trend at 10 mg/day. Adverse events were not significantly different in sarizotan‐ and placebo‐treated patients, but off time significantly increased with sarizotan 10 mg/day. Sarizotan 2 mg/day is a safe agent in PD patients with dyskinesia. To test its role in abating dyskinesia, future studies should focus on this dose and will use the composite score of UPDRS Items 32+33 as the primary outcome. © 2006 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000179 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000179 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:0DE4A22F865B7A74E84AF35376BF9D26DF62324C
|texte= Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial
}}
| This area was generated with Dilib version V0.6.23. |  |